Pelster, Meredith S.
Silverman, Ian M. http://orcid.org/0000-0003-3819-6726
Schonhoft, Joseph D.
Johnson, Adrienne
Selenica, Pier
Ulanet, Danielle
Rimkunas, Victoria
Reis-Filho, Jorge S.
Funding for this research was provided by:
Repare Therapeutics Inc.
Article History
Received: 6 March 2023
Accepted: 21 December 2023
First Online: 1 April 2024
Competing interests
: I.M.S., J.D.S., A.J., D.U., and V.R. are employees and own stock in Repare Therapeutics. J.S.R.F. declares personal/consultancy fees from and membership of the scientific advisory board of Repare Therapeutics. J.S.R.F. also reports personal/consultancy fees from Bain Capital, LP, Goldman Sachs, Paige.AI, Inc., SAGA Diagnostics, and Swarm, membership of the scientific advisory boards for Daiichi Sankyo, Merck, Paige.AI, Inc., Personalis, and Roche Tissue Diagnostics, and membership of the Board of Directors of Grupo OncoclĂnicas, outside the scope of this study. M.S.P. reports consulting fees paid to their institution from AstraZeneca, Bayer, CytomX Therapeutics, Daiichi Sankyo, Ipsen, Novartis, Pfizer Inc., and Seagen Inc., and research support to their institution from Arcus Biosciences, Astellas Pharma Inc., BeiGene, BioNTech, Bristol Myers Squibb, Codiak BioSciences, CytomX Therapeutics, Eisai, Gilead Sciences, Inc., Gritstone Oncology, HiberCell, Immune-Onc Therapeutics, Inc., Leap Therapeutics, OncXerna Therapeutics, Panbela Therapeutics, Inc., Revolution Medicines, Surface Oncology, SQZ Biotechnologies, Translational Genomics, TransThera Sciences, ZielBio, and 1200 Pharma, outside the scope of this study. P.S. has no competing interests to disclose.